Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
Xiao HanXiaoyong TangHui ZhuDongyuan ZhuXiqin ZhangXiangjiao MengYing HuaZhongtang WangYan ZhangWei HuangLinlin WangShuanghu YuanPinliang ZhangHeyi GongYulan SunYingjie ZhangZengjun LiuXiaomeng DongFei GaiZhan HuangChangbin ZhuJun GuoZhehai WangPublished in: Journal for immunotherapy of cancer (2023)
ctDNA status and ctDNA mutation clearance putatively serve as predictive biomarkers for sintilimab combined with docetaxel chemotherapy in pretreated advanced NSCLC patients.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- small cell lung cancer
- end stage renal disease
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- advanced non small cell lung cancer
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- radiation therapy
- brain metastases
- patient reported